AB-25B8

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameAB-25B8
Drug Alias NameAB-0326-targeting mAbs (Alethia)AB-25B8
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 agonists
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsOsteoporosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAlethia Biotherapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAlethia Biotherapeutics Inc
Active IndicationsN/A
Inactive IndicationsOsteoporosis

Other Information

ATC CodeN/A
Related LinksN/A